论文部分内容阅读
目的:研究多次小剂量131I-血管抑素(AS)放射受体治疗(RRT)对荷瘤小鼠肿瘤的治疗作用及其安全性。方法:采用荷Lew is肺癌小鼠模型,分别给予多次小剂量RRT、化疗、单次大剂量RRT治疗,观察14 d内肿瘤体积变化和小鼠生存期,并用免疫组化法检测各组肿瘤中CD34和核因子-κB(NF-κB)P65的表达以及正常小鼠RRT后体重、外周血白细胞和血小板的改变。结果:实验结果显示,多次小剂量RRT组小鼠生存期延长(P<0.05),疗效优于其他各组(P<0.01)。大、小两种剂量131I-AS对小鼠的白细胞、血小板数量无显著影响;免疫组化法检测显示,131I-AS治疗组肿瘤中CD34和NF-κB P65的表达明显低于单纯化疗组(P<0.01)。结论:多次小剂量RRT优于化疗;131I-AS小剂量放射免疫治疗对小鼠外周血白细胞、血小板无明显抑制作用。
Objective: To study the therapeutic effect and safety of multiple small doses of 131I-angiostatin (AS) radioreceptor therapy (RRT) on tumor-bearing mice. Methods: The Lew is lung cancer mouse model was given multiple low-dose RRT, chemotherapy and single high-dose RRT. The changes of tumor volume and survival time were observed within 14 days. Immunohistochemistry was used to detect tumors in each group. Expression of CD34 and nuclear factor-kappa B (NF-κB) P65 and changes in body weight, peripheral blood leukocytes and platelets after normal RRT. Results: The experimental results showed that the survival time of mice with multiple low-dose RRT groups was prolonged (P<0.05), and the curative effect was better than that of other groups (P<0.01). Both large and small doses of 131I-AS had no significant effect on the number of white blood cells and platelets in mice; immunohistochemistry showed that the expression of CD34 and NF-κB P65 in the 131I-AS treated group was significantly lower than that in the chemotherapy alone group ( P<0.01). Conclusion: Multiple low-dose RRT is superior to chemotherapy; 131I-AS low-dose radioimmunotherapy has no significant inhibitory effect on peripheral blood leukocytes and platelets in mice.